Yes, Skyrizi is FDA-approved to treat moderate-to-severe plaque psoriasis in adults. It received its initial approval in 2019 for people who are candidates for systemic therapy (medications that work throughout the body) or light-based treatment. In 2022, it also gained approval for psoriatic arthritis. It works by blocking a specific immune signal that drives the overproduction of skin cells in psoriasis.
How Skyrizi Works
Psoriasis is fueled by an overactive immune system, and a protein called IL-23 plays a central role. IL-23 triggers a chain reaction that causes skin cells to multiply far too quickly, leading to the thick, scaly plaques characteristic of the disease. Skyrizi is a biologic medication that binds to a specific part of IL-23 (called the p19 subunit), effectively neutralizing it before it can send that inflammatory signal.
Three biologic medications target this same subunit, but they each attach to it in slightly different ways. Research comparing the three found that Skyrizi binds to the largest surface area on the protein and holds on most tightly, which correlates with its higher rates of skin clearance in both short-term and long-term studies.
Who Qualifies for Treatment
Skyrizi is specifically indicated for adults with moderate-to-severe plaque psoriasis. In practice, this generally means psoriasis that covers a significant portion of the body, appears in areas that substantially affect quality of life (hands, feet, face, genitals), or hasn’t responded well enough to topical treatments like creams and ointments. Your dermatologist will assess severity using tools that factor in how much skin is affected and how thick or red the plaques are.
Before starting treatment, your doctor will screen you for tuberculosis and other infections. If you have a history of TB or an active infection, that needs to be addressed first. Blood tests to check liver function are also done before, during, and for at least 12 weeks into treatment.
Dosing Schedule
Skyrizi for psoriasis is given as a 150 mg injection under the skin. You receive your first dose at week 0, a second dose at week 4, and then one injection every 12 weeks after that. The every-12-weeks maintenance schedule is one of the less frequent dosing intervals among psoriasis biologics, which many patients find convenient. The injections can be self-administered at home with a prefilled syringe or pen after initial training.
How Quickly It Works
Some people notice improvement as early as four weeks, though dramatic clearance takes longer for most. Data from clinical trials tracked the percentage of patients who achieved a 90% reduction in their psoriasis severity score over time:
- 4 weeks: 6% of patients reached 90% clearance
- 8 weeks: 44% reached 90% clearance
- 16 weeks: 76% reached 90% clearance (compared to 5% on placebo)
- 52 weeks: 86% reached 90% clearance
By the one-year mark, 59% of patients achieved complete clearance, meaning no visible plaques at all. The trend in these numbers is worth noting: Skyrizi continues to build effectiveness over months, so early results don’t reflect the full picture. If you’ve been on it for only a few weeks without major changes, that’s expected.
Side Effects
In clinical trials involving over 1,300 patients, Skyrizi’s side effect profile was relatively mild. The most common reactions during the first 16 weeks, compared to placebo, were:
- Upper respiratory infections (colds, sinus infections, sore throats): 13% vs. 9.7% on placebo
- Headache: 3.5% vs. 2%
- Fatigue: 2.5% vs. 1%
- Injection site reactions (redness, bruising, mild pain): 1.5% vs. 1%
- Fungal skin infections (athlete’s foot and similar): 1.1% vs. 0.3%
Folliculitis (inflamed hair follicles) and hives occurred in less than 1% of patients but still more often than with placebo. Because Skyrizi works by dialing down part of the immune response, the slight uptick in infections makes biological sense. However, it targets IL-23 specifically rather than broadly suppressing immunity, which keeps the overall infection risk relatively low compared to older immunosuppressive treatments.
What Type of Psoriasis It Treats
The FDA approval covers plaque psoriasis specifically, which is the most common form, accounting for roughly 80-90% of all psoriasis cases. If you have other variants like guttate, pustular, or erythrodermic psoriasis, Skyrizi is not specifically approved for those, though dermatologists sometimes use biologics off-label depending on the clinical situation.
Skyrizi is also approved for psoriatic arthritis, the joint inflammation that develops in up to 30% of people with psoriasis. So if you have both skin plaques and joint pain or stiffness, a single medication could potentially address both. The dosing for psoriatic arthritis is the same 150 mg every 12 weeks schedule after the initial loading doses.
How It Compares to Other Biologics
Skyrizi belongs to the newest class of psoriasis biologics, the IL-23 inhibitors. Older biologics target different immune pathways, including TNF-alpha and IL-17. Among IL-23 inhibitors, Skyrizi has shown the strongest binding affinity to its target protein, and this translates to the highest rates of skin clearance in both short-term and long-term data.
Head-to-head trials have also compared Skyrizi to other biologics outside of psoriasis. In Crohn’s disease studies against an older biologic that targets both IL-12 and IL-23, Skyrizi demonstrated superior long-term outcomes and a lower rate of serious adverse events (10.3% vs. 17.4%). While those results are from a different condition, they reinforce the favorable safety and efficacy profile of the IL-23-specific approach.
The practical difference for most patients comes down to clearance rates and dosing convenience. With 86% of patients reaching near-complete clearance by one year and injections only every 12 weeks during maintenance, Skyrizi sits at the higher end of both measures among current psoriasis biologics.